FDA To Update Quality Metrics Guidance
It's the only addition to the agency's 2016 agenda.
You may also be interested in...
Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.
Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.
Data developed to show no clinically meaningful differences with the reference product could confuse prescribers, agency says in new draft guidance.